Hire A Regulatory Affairs Specialist Who Owns Change Control, Not Document Assembly

What Does an AI-Fluent Regulatory Affairs Specialist Own That a Traditional One Doesn't?

The deficiency letter runs three pages and only one paragraph is about the device. The rest asks how the model was trained, which populations the training data covered, how anyone will know if performance drifts, and what happens the next time it is retrained. Your regulatory lead cannot answer a line of it without the data science team in the room. That gap is the job.

Work moves into this seat that was never in the old one, and it starts with evidence strategy for the algorithm: deciding, before the clinical work is designed, what a reviewer will want to see about data provenance, subgroup performance, the reference standard the model was measured against, and the failure modes nobody has looked for yet. That decision is made months before it is written up, and it is made by whoever is fluent in both vocabularies.

The predetermined change control plan lands here too. An adaptive model is not a static product, and the plan is the document that draws the line between updates inside the cleared envelope and updates that require going back. Writing it means knowing what engineering can actually verify on a release cadence, and maintaining it means auditing that each shipped update stayed inside the line. In the United States this sits with device review; in Europe it interacts with the medical device regime and with newer AI-specific obligations. Both regimes have been moving, so treat this paragraph as orientation and confirm current expectations with regulatory counsel rather than with a page like this one.

The drafting itself has changed hands as well. Submissions are machine-drafted now, and the specialist is accountable for every sentence a model produced on their behalf. A fabricated citation in a regulatory file is worse than a gap, because a gap reads as incomplete and a fabrication reads as a quality system that does not work.

Demand for this combination is not speculative. AI-fluent regulatory roles have been named among the fastest-growing areas of life sciences hiring for 2026 alongside bioinformatics and digital trial design ¹. No public series times a search for this exact title, so treat any precise number you are quoted with suspicion. What is measurable is the direction of the market around it: across roughly one billion job advertisements, roles asking for AI skills carried an average wage premium of 62 percent ². A seat that needs both that fluency and a submission history sits in the thinner part of that pool. Plan the search on that basis, not on how long your last regulatory hire took.

Which Tells Separate Real AI Fluency From Regulatory Vocabulary?

Almost every candidate will say the right words about validation, drift and transparency. The separation happens when you ask for a specific decision they made and what it cost. Real fluency sounds like an argument they lost, a piece of evidence they insisted on generating early, or a model update they refused to let ship. Performed fluency sounds like a framework summary with no dates in it.

The reference standard is the first thing a real one asks about, usually inside ten minutes, because a model's performance number means nothing without knowing what it was compared against and who adjudicated the disagreements. Close behind it comes the locked-or-adaptive question, which anyone who has defended a file raises before scoping anything: the whole shape of the submission and the change control plan turns on that distinction, and a candidate who does not ask will scope the wrong quarter of work.

Then give them the scenario that separates the rest. A retrain on six months of new data improves overall sensitivity and quietly drops it in one subgroup, and the question is whether that update ships. The answer matters less than whether they ask for the subgroup breakdown before they give one. The same instinct shows up on data provenance, which cannot be reconstructed after collection, so the people who have been burned ask about consent, licensing and site agreements before the clinical study starts rather than during the write-up.

What arrives without prompting, if the person is real, is the checking. They describe verifying a model's output as a matter of course, and the useful version is specific: a summary that inverted a hedge, or two cited sections that did not exist in the enrolled text. They also write for the reviewer rather than for the file. Hand them a paragraph of engineering description and ask for the version a reviewer reads once. Compression under accuracy is the whole craft, and it does not survive being faked.

One anti-tell. A candidate who offers to detect which parts of a document were written by a model is selling something that does not work, and it is the wrong question anyway. What matters is whether the person can stand behind the claims, name their sources and show the checking. If the concern is that a claimed submission history might not be real, that is a reference and records problem handled the ordinary way, closer to what a candidate verification analyst does than to any artifact test.

Which Backgrounds Actually Survive an Algorithm Deficiency Letter?

The obvious feeder is a device or pharma regulatory affairs specialist who has been quietly handling the software submissions. The less obvious ones are better than their resumes look: clinical validation scientists from diagnostics, biostatisticians who have written statistical analysis plans a reviewer questioned, software quality engineers from safety-critical industries, and model risk validators from banking who spent a decade proving somebody else's model behaved as documented.

Sort the feeders by which paragraph of that three-page letter they could have answered cold. Diagnostics validation people transfer unusually well. They already think in terms of a reference standard, a claimed population, and performance that has to hold outside the development set, which is most of what an algorithm submission argues. Biostatisticians bring the habit of pre-specifying an analysis and living with it. Model risk validators bring the one instinct hardest to teach, which is that a change to the system is an event requiring re-assessment rather than a routine release.

How the good ones got good is worth asking directly, because the answers are diagnostic. The strongest candidates describe using generative tools constantly on real work and building checking routines around them: drafting a section from the technical file and then verifying every regulatory reference against the primary text, asking a model to argue the reviewer's side of a weak claim, generating the deficiency questions they expect so the team can answer them before they arrive. Those are not tool demonstrations. They are the job rehearsed cheaply.

The failure pattern on this axis is not the person who avoids the tools. It is the person who trusts them. Ask what a model got wrong for them last month. Anyone doing this work seriously has a recent, specific answer, and anyone who does not has either not been doing it or has not been checking.

One more thing the seat carries that rarely appears in the job description: teaching discovery and clinical teams what evidence to preserve, in what form, starting the week the project opens. That is internal enablement, and it succeeds or fails on the same skills an HR AI enablement partner needs, which is why the regulatory hire should be judged partly on how they explain a constraint to people who did not ask for one.

Recruit Where Change Control Plans and Algorithm Evidence Already Get Written

Go where the artifact already exists. Regulatory affairs professional bodies such as RAPS, digital health and software-as-a-medical-device working groups, standards communities around risk management and software lifecycle for medical devices, and the clinical validation groups inside diagnostics companies all concentrate people who have defended an algorithm rather than read about one. A general job board returns commentary; these venues return practitioners.

Feeder employers follow the same logic. Imaging and diagnostics manufacturers have been clearing algorithm-containing products for years and have the deepest bench. Contract research organizations and regulatory consultancies rotate people across many submissions quickly, which compresses experience. Large pharma digital health groups and the regulatory teams at established SaMD companies hold the people who have written a change control plan and then lived under it.

Search on adjacent titles, because the market has not settled on a noun: regulatory affairs specialist AI and SaMD, digital health regulatory lead, software regulatory affairs manager, regulatory strategy lead for digital products, clinical validation and regulatory scientist. Set alerts on the duty rather than the title.

Screen on documents. Ask every candidate for something they wrote that an external party relied on, redacted as needed: a submission section, a change control plan, a response to a deficiency letter, a validation report. Read it before the conversation. Then ask them to walk you through the one paragraph they rewrote most, and why. This is a writing and evidence job, and the samples are more honest than any credential in the field.

How Do You Close Someone Who Has Been Overruled by a Launch Date?

Close on standing first. The people worth hiring have all been overruled by a launch date at least once, so the offer conversation should name who they report to, what they can hold, and how an override gets written down. A regulatory seat reporting into the product organization it is meant to constrain reads as decorative, and strong candidates decline it politely.

On pay, be careful about numbers you cannot source. No public wage series covers this title specifically, and this piece is not going to invent a band for it. What can be said honestly is directional: the market clears above general regulatory affairs because the supply constraint is real. The only wide measurement available is economy-wide rather than specific to this seat: roles asking for AI skills carried an average wage premium of 62 percent across roughly one billion job advertisements ². That is an average across every occupation, not a band for this title, and it should be read as a direction rather than a number to offer against. Benchmark against your own accepted offers and against device regulatory bands in your region, add for the software and algorithm scope, and expect competing offers from diagnostics and digital health companies rather than from your usual comparison set. Anyone quoting you a precise national figure for this exact title should be asked where it came from.

What kills the offer is predictable. A scope that turns out to be submission clerking with a modern title. A change control plan already written by someone else that the new hire is expected to inherit and defend without authority to change it. No budget for external expertise on the algorithm side, which reads as a signal about how seriously the mandate is meant. And a slow process, which in a market this thin simply hands the candidate to whoever moved faster.

On location, most of this work travels. Drafting, evidence strategy, plan maintenance and reviewer correspondence are all remote-friendly, and postings for the title are commonly remote or hybrid. Three parts resist it. Meetings with a regulator or notified body are often in person and in a specific jurisdiction. Clinical site visits and design history reviews go badly over video. And residency or establishment requirements attach to certain regulatory roles in certain markets, so check the specific obligation with counsel before writing a location-flexible offer. Remote with scheduled on-site weeks, plus any named residency requirement stated in the offer itself, is the arrangement that survives contact with the first submission. The test a year in is the letter you started with: whether your specialist can answer every paragraph of it without borrowing the data science team for a week.

Read the evidence >